Clodronate - Adjuvant treatment to prevent bone metasases

CANCER: A Wake-up call

What is Clodronate and what does it do?

Clodronate is a member of a class of drugs called bisphosphonates, which are used to treat the bone-thinning disease osteoporosis – It has been around for 20 years, and is a drug that actually heals, rather than just treats symptoms.

Studies from Europe show it can:

Reverse bone loss;
Significantly increases lumbar bone density. Especially when mixed with calcium;

But most importantly:

Clodronate is an effective adjunct to any therapy you are using for the purpose of preventing bone metastases. A major benefit for those with breast cancer, where the majority of deaths occur after the cancer has metastasized to the bones.

It has minimal side effects and does not kill cancer cells
FDA issued an approvability letter in 2005 for clodronate as a breast cancer adjuvant treatment – although, despite its approvability letter, it is not officially FDA-approved.

Some studies using clodronate

Clodronate ought to be seriously considered as an adjuvant treatment for Stage II and III breast patients. Given some of the favorable trial results below, its safe nature and relatively inexpensive cost (under $200 per month from Canada), in addition to its benefit in reducing bone loss in breast cancer patients simultaneously receiving anti-estrogen therapy.Newer/future generation bisphosphonates may have even more potent anti-cancer potential than Clodronate.

2009 – Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Improves overall survival in men with metastatic prostate cancer who are starting hormone therapy, but there is no evidence of an effect in men with non-metastatic prostate cancer.
2006 – a large randomized double-blinded placebo controlled multi-center study of over one thousand patients over 5 years confirmed reduced skeletal metastasis as well as possibly favorable survival in breast cancer patients (esp those with Stage II or III disease rather than Stage I) receiving clodronate as adjuvant over the initial 2 years.
2001 – Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. This Finnish study showed a decrease in survival in clodronate treated breast cancer patients,
1998 – Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment. Study concluded that Clodronate can reduce the incidence and number ofnew bony and visceral metastases in women with breast cancerwho are at high risk for distant metastases.
1993 –Paterson et al. Noted reduced bone-related morbidity in treated patients and recommended that Clodronate be further investigated for potentially reducing bone metastasis as an adjuvant treatment for those who are at risk.
1988 – breast cancer patients with multiple bone metastasis treated with clodronate experienced fewer fractures and less hypercalcemia, with a higher survival rate and no side effects. [Biomed. Pharmacother. (France), 42/2 (111-1160];
1987 – two studies showed that oral clodronate successfully reduced a mean serum calcium concentration in 22 our of 25 patients with various types of malignant tumors, and that clodronate is a valuable clinical tool in the management of patients with malignancy-associated hypercalcemia. [Acta. med. Scand. (Sweden), 221/5 (489-494)];
1985 – clodronate given to patients with episodes of hypercalcemia and osteolysis due to carcinoma reduced serum calcium in 14 of 17 episodes and bone resorption in all patients. [Br. J. Cancer (England), 51/5 (665-669)];
1984 – published in both France and the US, this study concluded that “Clodronate is very effective against osteoclasts,” and “Clodronate may be a useful adjuvant in managing metastatic bone disease.” [Presse Med. 13/8, 479-482); New England Journal of Medicine, 308/25 (1499-1501)];
1998 – Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Article – Clodronate does not improve breast cancer survival

Contraindications for taking clodronate

You should not use clodronate with any of the following conditions:

If you suffer from severe renal insufficiency (a kidney disorder requiring dialysis);
If you are pregnant or breast-feeding
Hypersensitivity to Clodronate or to other bisphosphonates.
Severe inflammation of the gastrointestinal tract.

More information at: https://www.ndrugs.com/?s=clodronate

How to take clodronate

Standard Dosage for treating cancer is 800 mg of clodronate taken orally twice daily. According to the Life Extension Foundation, although twice this dosage has been used safely.

Take on empty stomach, preferably an hour before eating – otherwise reduces dose into bloodstream.

Breast cancer patients might want to consider a 3 – 5 year regimen on clodronate therapy

Monitor calcium levels and kidney function. Blood tests to measure serum calcium levels and kidney function should be done 10 days after initiating clodronate therapy and every one to two months thereafter. In a small minority of patients. Clodronate will cause too much calcium to be pulled from the blood to the bone.